Immunovia, Inc has received final approval to begin patient testing for the IMMray PanCan-d test.Contents hide • ocultar1. Immunovia, Inc has received final approval to begin patient testing for the IMMray PanCan-d test.
The IMMray PanCan-d test is the first blood test on the market dedicated to the early detection of pancreatic cancer.
“We are extremely pleased to have achieved this important milestone and to be able to launch the first non-invasive, highly accurate blood test that can help detect pancreatic cancer in early stages. The IMMray PanCan-d test meets a huge clinical need and our ambition is to make the test available to individuals in all the high-risk groups for pancreatic cancer. As a first step, we will launch the test for the familial/hereditary high-risk group,” says Patrik Dahlen, Immunovia’s CEO.
— Read on nordiclifescience.org/immunovia-inc-to-begin-patient-testing-in-the-us/
Oxygen Monitor – Oxímetros en AmerExperience.com/HEALTH ❤️
Fingertip Oxygen Monitor – This Device Can Save Your Life
🇪🇨 Seguros Ecuador